Bharat Biotech seeks DCGI nod for phase-3 trials of intranasal COVID vaccine as booster dose

Bharat Biotech has sought the Drug Controller General of India’s approval to conduct phase-3 trials of its COVID-19 intranasal vaccine (BBV154) to use as booster dose, sources said on Monday. “The application has been filed and the company is awaiting approval from the drug regulator. The intranasal vaccine will be administered to those who have already taken their two-dose vaccine,” the sources told PTI.

Credits – Source – https://ift.tt/3J7NPfe

The post Bharat Biotech seeks DCGI nod for phase-3 trials of intranasal COVID vaccine as booster dose appeared first on Stay in Gurgaon.

Comments

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

10YearsForSimha: Reasons behind film’s success

Hrithik-Saif’s Vikram Vedha hits a roadblock